Twist Bioscience Enters Royalty Purchase Agreement With XOMA Royalty; XOMA To Provide Twist With $15M Upfront Payment In Exchange For Right To Receive Half Of Future Potential Milsetones Earned Under Antibody Discovery And Biopharma Services Collaborations
Portfolio Pulse from Benzinga Newsdesk
Twist Bioscience has entered into a royalty purchase agreement with XOMA Corporation. XOMA will provide Twist with a $15 million upfront payment in exchange for the right to receive half of future potential milestones earned under Twist's antibody discovery and biopharma services collaborations.
October 22, 2024 | 12:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Twist Bioscience will receive a $15 million upfront payment from XOMA, which could enhance its cash position and support its operations. The agreement also involves sharing future milestone earnings, potentially impacting future revenue streams.
The $15 million upfront payment improves Twist's cash flow, which is beneficial for its operations. Sharing future milestone earnings could lead to additional revenue, positively impacting Twist's financial outlook.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
XOMA Corporation will pay $15 million upfront to Twist Bioscience for the right to receive half of future potential milestones. This investment could lead to significant returns if Twist's collaborations are successful.
XOMA's $15 million investment in Twist Bioscience could yield substantial returns if Twist's antibody discovery and biopharma services collaborations achieve significant milestones, enhancing XOMA's revenue potential.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 85